Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00LGR
|
|||
| Drug Name |
TP-0903
|
|||
| Synonyms |
YUAALFPUEOYPNX-UHFFFAOYSA-N; 1341200-45-0; TP0903; UNII-14D65TV20J; CHEMBL2022968; compound 13; 14D65TV20J; TP 0903; 2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide; GTPL8863; SCHEMBL12813478; EX-A609; MolPort-039-193-844; ZINC84617535; BDBM50382425; AKOS026750306; CS-4281; DA-45909; HY-12963; S7846; FT-0700169; B5940; J-690134; 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzene-1-sulfonamide
Click to Show/Hide
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 1/2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [2] | ||
| Company |
Tolero Pharmaceuticals Lehi, UT
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H30ClN7O2S
|
|||
| Canonical SMILES |
CN1CCN(CC1)CC2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)N(C)C)Cl
|
|||
| InChI |
1S/C24H30ClN7O2S/c1-30(2)35(33,34)22-7-5-4-6-21(22)28-23-20(25)16-26-24(29-23)27-19-10-8-18(9-11-19)17-32-14-12-31(3)13-15-32/h4-11,16H,12-15,17H2,1-3H3,(H2,26,27,28,29)
|
|||
| InChIKey |
YUAALFPUEOYPNX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1341200-45-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tyrosine-protein kinase UFO (AXL) | Target Info | Inhibitor | [2] |
| NetPath Pathway | FSH Signaling Pathway | |||
| Pathway Interaction Database | Validated transcriptional targets of deltaNp63 isoforms | |||
| Reactome | VEGFA-VEGFR2 Pathway | |||
| WikiPathways | miR-targeted genes in squamous cell - TarBase | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03572634) Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.